posted on 2021-11-02, 04:25authored byGiovanna Pesante, Federico Sabbadin, Luisa Elias, Clare Steele-King, J. Reuben Shipway, Adam A. Dowle, Yi Li, Marta Busse-Wicher, Paul Dupree, Katrin Besser, Simon M. Cragg, Neil C. Bruce, Simon J. McQueen-Mason
Additional file 13: Fig. S8. MALDI-TOF MS analysis of in vitro activity assays with purified LpsAA10A under the same experimental conditions as in Fig. 5 C. Panels from a to d show spectra of products obtained after incubation of the enzyme with 4 mg mL-1 Avicel (a), 4 mg mL-1 Avicel plus 4 mM gallic acid (b), 4 mg mL-1 Avicel plus 2 μM LPMO (c) and 4 mg mL-1 Avicel plus 2 μM LPMO and 4 mM gallic acid (d). In panels a to d, 100% relative intensity represents 1.3 × 104 arbitrary units (a.u.). The panels from e to g show spectra of products obtained after incubation of 4 mg mL-1 PASC (e), 4 mg mL-1 PASC plus 4 mM gallic acid (f) and 4 mg mL-1 PASC plus 2 μM LPMO (g). In panels e to g, 100% relative intensity represents 1.0 × 104 arbitrary units. File format .DOCX.
Funding
Biotechnology and Biological Sciences Research Council